In contrast, RASAL2 is upregulated in triple-negative breast cancer and oestrogen-receptor negative breast cancer and is associated with poor prognosis, early metastasis, and tumour recurrence [8–10]. This evidence concerns the gene RASAL2 and neoplasm.